BIOSIMILARS IN RHEUMATOLOGY
One of the most striking achievements in the pharmacotherapy of rheumatoid arthritis (RA) and other human immunoinflammatory diseases (IIDs) late in the 20th century is associated with the design of a fundamentally new group of medications that received the name biological agents (BAs). However, the...
Saved in:
Main Author: | E. L. Nasonov |
---|---|
Format: | Article |
Language: | Russian |
Published: |
IMA PRESS LLC
2017-01-01
|
Series: | Научно-практическая ревматология |
Subjects: | |
Online Access: | https://rsp.mediar-press.net/rsp/article/view/2316 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Evaluating the effect of a Russian rituximab biosimilar used to treat patients with rheumatoid arthritis on healthcare budgets
by: R. O. Dreval
Published: (2018-06-01) -
Comparison of the efficacy and safety of the original rituximab and its biosimilar in routine clinical practice
by: D. A. Kusevich, et al.
Published: (2022-06-01) -
The results of investigating the efficacy and safety of non-medical switching from the original rituximab to its biosimilar in rheumatoid arthritis patients (AMBIRA study)
by: M. A. Korolev, et al.
Published: (2021-01-01) -
Highly effective treatment options for rheumatoid arthritis afforded by the availability of biosimilars
by: Leticia A. Shea, et al.
Published: (2025-03-01) -
Dynamics of the level of calprotectin in patients with rheumatoid arthritis during rituximab biosimilar (Acellbia “Biocad”) therapy
by: A. S. Avdeeva, et al.
Published: (2021-09-01)